01 Industry overview
The biomanufacturing industry at a glance
U.S. biological-product manufacturing employed 46,936 people in 2025, up 15.8% from 2021, while broader biomanufacturing value added was $438.8 billion in the latest available NIST estimate.
- 46,936[4]
- U.S. biomanufacturing jobs, 2025
- 15.8%[4]
- Employment growth, 2021–2025
- $438.8B[13]
- U.S. biomanufacturing value added
- 12.84%[3]
- Digital biomanufacturing CAGR, 2026–2034
- Market size
- The latest broad U.S. estimate found $438.8 billion in direct biomanufacturing value added, with an additional $925.0 billion in indirect supply-chain and other value added, bringing the total to $1.364 trillion. This is the latest available NIST estimate and refers to 2021 economic activity.[13]
- Forecast & CAGR
- The narrower global digital-biomanufacturing market was valued at $22.44 billion in 2025 and is projected to reach $66.14 billion by 2034, implying a 12.84% CAGR from 2026 to 2034. The segment includes manufacturing-execution software, automation, digital twins, analytics and related services.[3]
- Market share & regions
- Global biomanufacturing capacity totaled 6,692 kL in 2024, including 2,467 kL in Europe, 2,340 kL in North America and 1,885 kL in Asia. On this capacity measure, Europe represented about 36.9%, North America 35.0% and Asia 28.2%.
- Segmentation
- The focused U.S. industry proxy is NAICS 325414, biological product manufacturing excluding diagnostics. It covers biologic medicines such as vaccines, therapeutic proteins, monoclonal antibodies, and blood- and plasma-derived therapies, while some cell and gene therapy, mRNA, viral-vector, fill-finish and multiproduct operations may be classified elsewhere.[4]
- Key players & concentration
- U.S. employment is geographically concentrated: 77% of the 46,936 biological-product-manufacturing jobs in 2025 were located in 12 states, although 45 states had some employment in the sector. Major biopharmaceutical manufacturers and contract manufacturers compete across process development, commercial production, fill-finish and specialized modalities.[4]
- Pricing
- Labor costs are a major pricing variable: a 2025 BIO submission cited U.S. entry-level bioprocess-engineer salaries of $75,000–$95,000, compared with $15,000–$21,000 in China. The same source estimated that producing one kilogram of a protein therapeutic can require up to 30,000 kilograms of water, adding significant operating-cost pressure.[4]
- Trends, drivers & challenges
- Demand is being supported by biologic medicines, contract development and manufacturing, advanced production systems and efforts to diversify domestic supply chains. Capacity expansion remains constrained by specialized workforce shortages, with a 2025 BIO submission citing more than 60,000 unfilled U.S. biomanufacturing positions, alongside high labor, energy, water and compliance costs.[4]
- M&A
- M&A activity strengthened in Massachusetts in the first half of 2026: 11 companies were acquired for a reported $18.0 billion, compared with $7.6 billion at the same point in 2025. In August 2026, Xcellon Biologics also agreed to acquire NextCure’s 40,000-square-foot GMP facility to expand its integrated CRDMO platform.[14][15]
- Regulation
- In May 2026, the U.S. FDA issued immediate-implementation guidance on chemistry, manufacturing and controls flexibilities for cellular and gene-therapy products submitted for biologics licenses. In November 2026, FDA also issued final guidance recommending science- and risk-based potency controls across development, manufacturing and commercialization.[16]
- Latest news
- Genentech reached the structural-framework milestone for its $2 billion Holly Springs, North Carolina biomanufacturing facility in August 2026; the project is expected to support more than 500 high-wage manufacturing roles. Amgen separately announced $300 million of additional U.S. manufacturing investment in May 2026, bringing its announced U.S. manufacturing investment over the prior year to nearly $2 billion.[17][18]
02 Ranking
Top 10 Companies in the Biomanufacturing Industry
The leading companies in the biomanufacturing industry, ranked on market impact, performance, momentum, innovation and brand popularity.
Updated November 18, 2026 · Next review December 18, 2026
Eli Lilly and Company stands out for large-molecule biologics manufacturing expansion because it is expanding manufacturing for monoclonal antibodies, bioconjugates and other large molecules, while Samsung Biologics focuses on commercial antibody manufacturing since Plants 1 through 4 support large-scale production for global customers.
Ranked by Overall score · How we score ↓
Editor's top 3 picks
Where to start, by need.
#1 Overall · Leader in biologic manufacturing
Eli Lilly and Company
US
Ranked #1 · 9.3 · Biologic manufacturing
Why we picked it: It combines expansion in large-molecule manufacturing with an an operating margin of 40.4% and revenue growth of 44.7%.
Leader in antibody CDMO
Samsung Biologics
KR
Ranked #2 · 9.1 · Antibody CDMO
Why we picked it: Its CDMO scale for commercial antibodies is paired with an an operating margin of 45.4% and revenue growth of 30.3%.
Leader in vaccines manufacturing
Serum Institute of India
IN
Ranked #3 · 9.1 · Vaccines manufacturing
Why we picked it: Its vaccine manufacturing footprint aligns with an estimated 36% revenue growth.
Pick 1 is the #1 company overall. Picks 2 and 3 are the highest-ranked companies in the top 5 that add a new segment.
Full ranking
| # | Company | Overall ↓ | Impact | Performance | Momentum | Innovation | Company snapshot |
|---|---|---|---|---|---|---|---|
| 1 | Eli Lilly and Company Biologic manufacturing · US | 9.3 | 8.8 | 9.9 | 9.9 | 9.9 | |
Company snapshot · Eli Lilly and Company · Data as of November 18, 2026 Expanding manufacturing for monoclonal antibodies, bioconjugates and other large molecules.[19]
| |||||||
| 2 | Samsung Biologics Antibody CDMO · KR | 9.1 | 8.7 | 9.9 | 9.9 | 8.8 | |
Company snapshot · Samsung Biologics · Data as of November 18, 2026 Plants 1 through 4 support large-scale commercial antibody manufacturing for global customers.[20]
| |||||||
| 3 | Serum Institute of India Vaccines manufacturing · IN | 9.1 | 8.8 | 9.9 | 9.2 | 8.8 | |
Company snapshot · Serum Institute of India · Data as of November 18, 2026 Produces more than 1.5 billion vaccine doses annually for around 170 countries.[21]
| |||||||
| 4 | Lonza Biopharma CDMO · CH | 9.0 | 9.3 | 9.0 | 9.3 | 7.6 | |
Company snapshot · Lonza · Data as of November 18, 2026 Operates more than 30 global development and manufacturing sites across biopharma modalities.[22]
| |||||||
| 5 | Thermo Fisher Scientific Biologics CDMO services · US | 8.8 | 9.9 | 7.9 | 8.4 | 7.4 | |
Company snapshot · Thermo Fisher Scientific · Data as of November 18, 2026 Provides contract development and manufacturing services for biologics and advanced therapies.[23]
| |||||||
| 6 | Roche Branded biologics and diagnostics manufacturing · CH | 8.8 | 8.8 | 8.0 | 8.9 | 9.9 | |
Company snapshot · Roche · Data as of November 18, 2026 Operates large-scale manufacturing and production processes for biologic medicines.[24]
| |||||||
| 7 | Pfizer Vaccines, biologics and gene-therapy manufacturing · US | 8.4 | 8.8 | 8.0 | 7.5 | 9.2 | |
Company snapshot · Pfizer · Data as of November 18, 2026 Operates manufacturing sites for biologics, vaccines, antibody-drug conjugates and gene therapies.[25]
| |||||||
| 8 | Fujifilm Biopharmaceutical CDMO through Fujifilm Diosynth · JP | 8.3 | 8.7 | 7.7 | 8.4 | 8.0 | |
Company snapshot · Fujifilm · Data as of November 18, 2026 Its Fujifilm Diosynth organization provides clinical and commercial biopharmaceutical manufacturing.[26]
| |||||||
| 9 | AGC Biologics Global biologics and advanced-therapy CDMO · US | 8.1 | 7.0 | 8.4 | 8.9 | 9.3 | |
Company snapshot · AGC Biologics · Data as of November 18, 2026 Provides cGMP manufacturing for proteins, viral vectors, cell therapies, mRNA and plasmid DNA.[27]
| |||||||
| 10 | Recipharm Pharmaceutical and advanced-biologics CDMO · CH | 7.7 | 7.3 | 8.0 | 7.9 | 8.8 | |
Company snapshot · Recipharm · Data as of November 18, 2026 Manufactures biologics, viral vectors, mRNA and plasmid DNA through its Advanced Bio segment.[28]
| |||||||
How we score
- Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
- Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
- Momentum (20%): growth trajectory and future potential.
- Innovation (15%): R&D intensity and how technologically advanced the company is.
Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.
Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.
Cadence Recalculated when new figures are published; next review December 18, 2026.
Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.
Cite this ranking
APA
Samuel Norberg. (2026, November 18). Top 10 companies in the biomanufacturing industry. In Biomanufacturing Industry Statistics. Gitnux. https://gitnux.org/biomanufacturing-industry-statistics/#top-companies
Biological product manufacturing employment by state (United States)
North Carolina leads with 6,816.
03 Trends & forecasts
Top 10 Biomanufacturing Industry Trends & Forecasts 2027
What is changing in the biomanufacturing industry, with the evidence behind each trend and a forecast for 2027.
Forecasts were generated by an AI model from the cited evidence. They are estimates, not guarantees.
01Biologics demand continues rising
High confidenceDemand for biomanufacturing is being supported by expanding biologics portfolios, including therapeutic proteins, monoclonal antibodies, vaccines and advanced therapies. U.S. biological-product manufacturing employment reached 46,936 in 2025, up 15.8% from 2021.[4]
Forecast 2027: In 2027, biologics demand should remain the primary volume driver, with employment and manufacturing activity continuing to grow faster than mature pharmaceutical manufacturing. Growth will be strongest in complex biologics and therapies with differentiated clinical value.
02CDMO outsourcing expands further
High confidenceThe global biologics contract-development-and-manufacturing market grew 11% in 2024 to $20.7 billion, reflecting rising demand for complex manufacturing services. Executives surveyed in the 2024 CPHI Annual Report identified biologics as the investment area most likely to deliver the best marginal and overall CDMO returns over the following five years.[29][30]
Forecast 2027: In 2027, sponsors should continue shifting process development, clinical manufacturing and selected commercial production to CDMOs. Demand will favor providers that combine development, analytical, fill-finish and commercial capabilities rather than offering isolated production capacity.
03Global capacity keeps expanding
High confidenceGlobal biologics manufacturing capacity reached 6,692 kL in 2024, including 2,467 kL in Europe, 2,340 kL in North America and 1,885 kL in Asia. Capacity had increased from approximately 600 kL in 2000 to more than 6,700 kL in 2024.[30]
Forecast 2027: Capacity should increase again in 2027 as previously announced plants move through construction, qualification and commissioning. The additions will be concentrated in large-scale mammalian production, flexible multiproduct facilities and specialized advanced-therapy capacity.
04Supply chains become more regional
High confidenceU.S. companies are investing in domestic production to strengthen supply resilience: Amgen announced an additional $300 million of U.S. manufacturing investment in May 2026, bringing its announced U.S. manufacturing investment over the preceding year to nearly $2 billion. The company stated that the investment would expand domestic capacity and support supply-chain reliability.[18]
Forecast 2027: In 2027, regionalization should continue through domestic expansions, dual sourcing and geographically diversified manufacturing networks. Companies are unlikely to abandon global supply chains, but they will place greater value on redundant capacity for critical medicines and inputs.
05Digital biomanufacturing scales rapidly
High confidenceThe global digital-biomanufacturing market was valued at $22.44 billion in 2025 and is projected to reach $66.14 billion by 2034, implying a 12.84% CAGR from 2026 to 2034. The segment includes manufacturing-execution software, automation, digital twins, analytics and related services.[3]
Forecast 2027: By 2027, digital biomanufacturing spending should exceed the 2026 level as manufacturers modernize electronic batch records, process monitoring and quality systems. Adoption will be fastest at new facilities, where digital architecture can be designed into operations from the beginning.
06AI and advanced analytics gain ground
Medium confidenceDigital-biomanufacturing offerings increasingly include artificial intelligence, machine learning, advanced analytics, modeling and simulation, alongside automation and process control. These tools are being positioned for process development, scale-up, commercial GMP execution and quality operations.[3]
Forecast 2027: In 2027, AI use should move from experimentation toward targeted production applications such as deviation investigation, predictive maintenance, process-drift detection and yield improvement. Regulated deployment will remain gradual because models must be validated and their decisions made auditable.
07Advanced modalities reshape facilities
High confidenceFDA issued immediate-implementation guidance in May 2026 describing flexibility in chemistry, manufacturing and controls requirements for human cellular and gene-therapy products submitted for biologics licenses. The agency’s November 2026 final potency guidance also addresses viral-vector products, short-shelf-life products and patient-specific therapies.[16]
Forecast 2027: In 2027, facility designs should become more modular and modality-flexible, with greater use of closed processing, smaller production suites, rapid testing and specialized viral-vector or cell-therapy infrastructure. Commercial-scale traditional biologics will remain the largest capacity base, but advanced modalities will attract disproportionate investment.
08Potency controls become more integrated
High confidenceFDA’s final November 2026 guidance recommends a science- and risk-based potency-assurance strategy covering process design, manufacturing controls, material controls, in-process testing and lot-release assays. This replaces the agency’s 2011 potency-testing guidance for cellular and gene therapies.[16]
Forecast 2027: In 2027, manufacturers of cellular and gene therapies should invest earlier in potency assays, reference materials, in-process testing and comparability strategies. The result will be higher quality-system costs in the near term but fewer late-stage manufacturing and release surprises.
09Workforce shortages constrain output
High confidenceA 2025 BIO submission estimated more than 60,000 unfilled U.S. biomanufacturing positions, including bioprocess-engineering and quality-assurance roles. The same submission cited entry-level bioprocess-engineer salaries of $75,000–$95,000 in the United States, compared with $15,000–$21,000 in China.[4]
Forecast 2027: In 2027, labor availability will remain a binding constraint on commissioning and operating new facilities. Employers will respond with technician-focused training, partnerships with community colleges, standardized digital work instructions and greater automation of repetitive operations.
10Labor and utility costs stay elevated
Medium confidenceBiomanufacturing faces high labor, energy, water and compliance costs. BIO reported that producing one kilogram of a protein therapeutic can require up to 30,000 kilograms of water, highlighting the operating-cost intensity of biologics production.[4]
Forecast 2027: In 2027, manufacturers should prioritize higher titers, improved downstream recovery, continuous or intensified processing and lower-water cleaning strategies. Cost pressure will favor facilities with efficient utilities and high asset utilization, while smaller firms will remain more dependent on CDMOs.
04 Statistics
Market Intelligence
We quantify 2025 market sizing across next-generation and digital biomanufacturing, including a $22.44 billion 2025 digital market and a $25.94 billion next-generation market estimate.
Market size, volume and shipments in the biomanufacturing industry
- $25.94 billion was the estimated 2025 global next-generation biomanufacturing market, covering single-use systems, continuous bioprocessing, modular facilities and cell-free systems; revenue measure.[1]
- $21.5 billion was the estimated 2024 global biomanufacturing market, covering biological production using living organisms, cells or biological systems; value measure, not physical volume.[2]
- $22.44 billion was the estimated 2025 global digital biomanufacturing market, covering software, connected equipment and services used in biomanufacturing; revenue measure.[3]
Forecast growth and shipments in the biomanufacturing industry
- The global next-generation biomanufacturing market was forecast to reach $60.85 billion by 2035, growing at 8.9% CAGR during 2026–2035; category covers single-use, continuous, modular and cell-free platforms.[1]
- The global biomanufacturing market was forecast to reach $31.5 billion by 2030 from $21.5 billion in 2024, implying 6.6% CAGR; category covers biological production using living organisms, cells or biological systems.[2]
- The global digital biomanufacturing market was forecast to reach $66.14 billion by 2034 from $25.16 billion in 2026, at 12.84% CAGR during 2026–2034; value measure.[3]
Company counts and size structure in the biomanufacturing industry
- 46,936 workers were employed in U.S. biological product manufacturing in 2025, up 15.8% from 2021; the measure uses NAICS 325414 and covers biologic medicines except diagnostics.[4]
- 78 U.S. biomanufacturing sites with toll capacity were listed in the BioP2P directory in April 2024; the directory covers facilities offering scale-up or commercial manufacturing capacity.[5]
- 45 U.S. states had employment in biological product manufacturing in 2025, while 36 states had at least 50 jobs; the measure uses NAICS 325414.[4]
05 Statistics
Strategy & Growth
We compile 2024–2025 facility and investment announcements, plus modality expansion signals like Fujifilm Diosynth’s 160,000 litres of additional mammalian-cell bioreactor capacity.
Capacity expansion in the biomanufacturing industry
- More than $26 billion in U.S. pharmaceutical and life-science manufacturing capital expenditure was pledged in 2025, including biomanufacturing facilities; the measure is announced investment, not commissioned capacity.[6]
- Nearly $50 billion in U.S. biomanufacturing-facility announcements accumulated across 2024–2025, almost 80% more than announcements made during 2020–2023.[6]
- Fujifilm Diosynth announced 160,000 litres of additional mammalian-cell bioreactor capacity at Holly Springs, North Carolina, with a $1.2 billion investment and production planned for 2028.[7]
- A biomanufacturing facility expansion in Tuas Biomedical Park, Singapore, was reported to add 120,000 litres of bioreactor capacity through a $1.4 billion investment.[8]
06 Statistics
Production & Operations
We separate productive-asset counts from company counts, showing 1,556 biopharmaceutical manufacturing facilities across 48 U.S. states and Puerto Rico.
Installed base and productive capacity in biomanufacturing
- 240 facilities and 140 companies were tracked for recombinant-protein bioproduction capacity serving U.S. and European markets in 2024.[9]
- 1,556 biopharmaceutical manufacturing facilities operated across 48 U.S. states and Puerto Rico; the source uses facilities as the productive-asset count, not companies, in its latest reported snapshot.[10]
- Nearly 20% of new U.S. biopharmaceutical manufacturing facilities produce active pharmaceutical ingredients, a capacity-use split within the 1,556-facility national base.[10]
- 2,362 European biorefineries and 479 European pilot, demonstration and semi-industrial plants were identified across bioeconomy manufacturing categories using JRC 2023 and Pilots4U 2024 data.[11]
07 Statistics
People & Workforce
We connect headcount pressure to output constraints, including 46,936 workers employed in 2025 and more than 60,000 unfilled positions reported in the U.S.
Employment and hiring in the biomanufacturing industry
- More than 60,000 positions were reported as unfilled in the U.S. biomanufacturing sector, including bioprocess-engineering and quality-assurance roles; the source does not provide a newer dated count.[4]
- 46,936 U.S. biological-product-manufacturing workers were employed in 2025, up 15.8% from 2021; the measure corresponds to NAICS 325414 and is a focused biopharmaceutical-biomanufacturing proxy.[4]
- 77% of U.S. biomanufacturing employment was concentrated in 12 states in 2025; the report defines the segment using NAICS 325414.[4]
- 45 U.S. states reported biomanufacturing employment in 2025, while 36 states had at least 50 biomanufacturing jobs.[4]
08 Statistics
Pricing & Finance
We track cost drivers using labor and water intensity examples, including $75,000–$95,000 entry-level bioprocess-engineer salaries in the U.S. versus $15,000–$21,000 in China.
Capex and investment in the biomanufacturing industry
- €60–200 million is the estimated investment range for smaller-scale, modular or specialised biotechnology production facilities in the European Union.[12]
- €316–428 million is the estimated investment range for large-scale biotechnology manufacturing facilities in the European Union, covering facility construction and production infrastructure.[12]
- $300 million was announced in May 2026 for Amgen’s expansion of a biologics manufacturing facility in Juncos, Puerto Rico, an example of U.S. biomanufacturing capital investment.[4]
- Hundreds of billions of dollars were announced for U.S. biomanufacturing facilities over the 12 months to August 2026, with projects covering more than 17 million square feet and 30,000 projected jobs over five to seven years.[4]
Key questions about the biomanufacturing industry
How large is the U.S. biomanufacturing value added market?
What growth rate is expected for digital biomanufacturing through 2034?
Which companies lead the biomanufacturing industry?
What technology shifts are most tied to near-term digital-biomanufacturing demand?
How concentrated is U.S. biomanufacturing employment geographically?
Where do supply constraints show up in workforce and capacity signals?
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
Samuel Norberg. (2026, November 18). Biomanufacturing Industry Statistics. Gitnux. https://gitnux.org/biomanufacturing-industry-statistics
Samuel Norberg. "Biomanufacturing Industry Statistics." Gitnux, 18 Nov 2026, https://gitnux.org/biomanufacturing-industry-statistics.
Samuel Norberg. 2026. "Biomanufacturing Industry Statistics." Gitnux. https://gitnux.org/biomanufacturing-industry-statistics.
Sources & references
30 sources cited across this report
emergenresearch.com
giiresearch.com
fortunebusinessinsights.com
bio.org
rss.globenewswire.com
enr.com
eu-assets.contentstack.com
- dcatvci.org
bioprocessintl.com
phrma.org
europabio.org
health.ec.europa.eu
tsapps.nist.gov
massbio.org
- xcellon.bio
fda.gov
gene.com
amgen.com
sustainability.lilly.com
samsungbiologics.com
seruminstitute.com
lonza.com
ir.thermofisher.com
roche.com
pfizer.com
fujifilmbiotechnologies.fujifilm.com
agcbio.com
recipharm.com
alirahealth.com
- projects.gbreports.com
